Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
… And Develop New Ones With Ablynx
by Ann M. Thayer
February 10, 2014
| A version of this story appeared in
Volume 92, Issue 6
Merck & Co. has joined with Ablynx to develop cancer immunotherapies. Merck will pay the Belgian company $27 million up front and up to $14 million in research funding. Ablynx could also receive milestone payments adding up to $2.3 billion. The goal is to use Ablynx nanobodies, or antibody-derived proteins that bind to disease targets, to modulate immune system checkpoints. In 2012, Ablynx signed another deal with Merck potentially worth more than $600 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X